Ocean Biomedical Reports Unregistered Equity Sales

Ticker: OCEA · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1869974

Sentiment: neutral

Topics: unregistered-securities, equity-sale, corporate-action

Related Tickers: OCEA

TL;DR

OCEA filed an 8-K for unregistered equity sales on Feb 11.

AI Summary

Ocean Biomedical, Inc. filed an 8-K on February 12, 2025, reporting unregistered sales of equity securities and other events that occurred on February 11, 2025. The company, previously known as Aesther Healthcare Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates potential dilution for existing shareholders due to the issuance of unregistered equity securities, which could impact the stock price.

Risk Assessment

Risk Level: medium — Unregistered sales of equity securities can lead to dilution and uncertainty about the terms of the issuance.

Key Players & Entities

FAQ

What type of equity securities were sold in the unregistered offering?

The filing does not specify the type of equity securities sold in the unregistered offering.

Were there any specific dollar amounts associated with the unregistered sales?

The filing does not disclose specific dollar amounts for the unregistered sales of equity securities.

What is the exercise price for the warrants mentioned?

The warrants mentioned have an exercise price of $11.50.

When did Ocean Biomedical change its name from Aesther Healthcare Acquisition Corp.?

Ocean Biomedical, Inc. changed its name from Aesther Healthcare Acquisition Corp. on February 14, 2023.

What is the Standard Industrial Classification (SIC) code for Ocean Biomedical, Inc.?

The SIC code for Ocean Biomedical, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-02-12 17:20:09

Key Financial Figures

Filing Documents

01 below

Item 8.01 below. Item 8.01 Other Information As of February 11, 2025, Ocean Biomedical, Inc. (the "Company") had 132,163,312 shares of its Common Stock issued and outstanding. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2025 OCEAN BIOMEDICAL, INC. By: /s/ Jolie Kahn Jolie Kahn Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing